This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In 1974, Dr. Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drugdelivery.
However, research related to metabolites is essential to increase the understanding of molecular level interactions, functions, modifications and regulations in cells, therefore, the field of metabolomics plays a vital role in biomarker discovery for early disease diagnosis and prognosis as well as for drug discovery and development processes.
Over the years, applications of exosomes in therapeutics have undergone an evolutionary change, in terms of cost of research, technology used, and duration of the study. Published Scientific Literature: Indicative of the Ongoing pace of Research in this Field. Our Social Media Platform. Web: [link]. LinkedIn: [link]. Twitter: [link].
Likewise, there are several other targets that have not yet been successfully drugged and researchers are making significant efforts to identify novel approaches to target them. As a result, novel product development opportunities have emerged and are likely to benefit both drug developers and investors alike.
In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material. Majority of the articles (51%) are focused on evaluating liposomes for use in cancer therapy.
Conjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Published Scientific Literature: Indicative of the Ongoing pace of Research in this Field. High Number of Patents are Suggestive of the Widespread Research in this Domain. Web: [link].
Therapies such as dexamethasone drugdeliverysystem and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Brolucizumab is a humanized single-chain antibody fragment (scFv).
Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. In a recent webinar, Dr. Vornov described the history and current progress in targeted CNS therapeutic delivery. Viral Vectors for Gene Delivery to the CNS.
Ligand-targeted Liposomes: These liposomes can be employed for site- specific targeting by attaching ligands (including antibodies, peptides, and carbohydrates) to their surface or to the terminal end of the attached PEG chains.
Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development. You can also download the SAMPLE REPORT on subcutaneous medications by Roots Analysis.
In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. During our research, we identified over 40 players that offer manufacturing services of biopharmaceutical excipients. Web: [link].
Vice President, Late Development and Global Medical Affairs, Janssen Research & Development, LLC. “We TAR-200 is an investigational drugdeliverysystem, enabling controlled release of gemcitabine into the bladder, increasing dwell time and local drug exposure. For more information, visit www.ERLEADA.com.
Amidst the ongoing initiatives to develop therapeutic interventions with improved bioavailability, lipid nanoparticle (LNPs) have specifically attracted the attention of researchers and drug developers. The LNPs can be monitored using various imaging modalities to confirm the delivery of siRNA to the target cells.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content